Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Ottobock Aktie 149106489 / DE000BCK2223

27.05.2026 10:00:03

iconiq: Individualized liner from a 3D printer.


EQS-Media / 27.05.2026 / 10:00 CET/CEST

iconiq: Individualized liner from a 3D printer.

Digital planning, additive manufacturing: residual limb problems affect up to 68 per cent* of prosthesis users – and this is exactly where the new silicone liner comes in.

Wednesday, 27 May 2026
Almost 68 per cent of leg prosthesis users have problems with their prosthesis. There are many causes, from pain or sores on the residual limb to physical reactions such as skin irritation. During this time, prostheses can be used only to a limited extent or not at all. The liner is the invisible base of a well-fitting leg prosthesis. It is crucial in terms of comfort, safety and mobility. This is a consumer product that needs to be replaced approximately every six months. In the past, O&P professionals had to choose between standardised liners with limited customisation options for their patients or complex and costly custom fabrications. With iconiq, Ottobock’s first 3D-printed silicone liner, the medtech champion is taking custom fittings to a new industrial level. The liner made its German premiere last week at OTWorld in Leipzig. The global market launch will now follow.

Oliver Jakobi, CEO/CSO of Ottobock, says: “The iconiq liner is an example of our strategy: to make our innovations available to as many users as possible, thereby providing them with high-quality fittings. The iconiq is another component in implementing this claim globally. With it, we offer an efficient solution without compromising on quality and precision.”
 

Redefining customised treatment.

“With iconiq, we are creating a future-proof solution that overcomes the existing conflict between standard solutions and customisation,” says Arne Jörn, CTO/COO at Ottobock. “We are industrialising customisation so that it no longer becomes the exception, but the norm in everyday care.”

The innovation focuses on additive manufacturing technology combined with an efficient digital process: a 3D scan of the residual limb is all it takes to generate a data set – without any markers or special equipment. The shape perfectly takes into account the user’s anatomy as well as sensitive areas and scar tissue. Once the residual limb length has been entered and the design selected on the Ottobock ordering platform, the data is transferred directly to the medtech company's production department. Production itself is carried out using 3D printing. This results in perfectly fitting, flexible liners without elaborate mould construction.
 

Designed for maximum requirements – provides simplicity for professionals.

O&P professionals benefit from consistent, reproducible results. As a result, customised liners can be produced faster, with improved planning and considerably less complexity.

With iconiq, users get a liner whose fit, shape and stability are precisely tailored to their individual needs. Different thickness profiles ensure uniform compression and a secure hold. The material properties are so versatile, even under high loads, that iconiq is suitable for users who have a very active or athletic lifestyle as well as for children and adults with mobility grade 2 and up.

 

* Internal market research study of Ottobock with 112 prosthesis wearers, 2023

 

Contact

Ottobock SE & Co. KGaA
Corporate Communications
Nadine Winter
Phone: +49 1511 888 3507
nadine.winter@ottobock.de


About Ottobock 

The publicly listed global medtech champion Ottobock combines over 100 years of tradition with outstanding innovation in the fields of prosthetics, neuro-orthotics and exoskeletons. Ottobock develops innovative fitting solutions for people with limited mobility and drives the digitalisation of the industry. Founded in Berlin in 1919, the company has nearly 9,300 full-time employees and is active in 45 countries today. It operates the largest international patient care network with around 420 patient care centres worldwide. With a strong R&D quota in the products and components business and more than 2,600 patents and patent applications, Ottobock is shaping the human bionics landscape of the future. The mission of improving people’s freedom of movement, quality of life and independence is deeply rooted in the company’s DNA – as is its social commitment: Ottobock has been a partner and supporter of the Paralympic Games since 1988. 



End of Media Release


Issuer: Ottobock SE & Co. KGaA
Key word(s): Enterprise

27.05.2026 CET/CEST Dissemination of a Press Release, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: Ottobock SE & Co. KGaA
Max-Näder-Strasse 15
37115 Duderstadt
Germany
Phone: +49 5527 848 - 0
E-mail: info@ottobock.com
Internet: https://corporate.ottobock.com
ISIN: DE000BCK2223
WKN: BCK222
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX; Vienna Stock Exchange
EQS News ID: 2333416

 
End of News EQS Media

2333416  27.05.2026 CET/CEST

In eigener Sache

Trading Signals: Richemont: Luxus-Titel mit Kaufsignal

Richemont sendet gleich doppelt Kaufsignale: Charttechnisch hat die Aktie wichtige Widerstände überwunden, fundamental stützen robuste Zahlen. Die Chancen stehen gut, dass der SMI-Titel das Jahreshoch ins Visier nimmt.

Weiterlesen!

Analysen zu Ottobock

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
20.05.26 Ottobock Buy Jefferies & Company Inc.
20.05.26 Ottobock Buy Goldman Sachs Group Inc.
14.05.26 Ottobock Buy Deutsche Bank AG
13.05.26 Ottobock Buy UBS AG
13.05.26 Ottobock Buy Jefferies & Company Inc.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Magnificent 7 im Check – Hype vorbei oder weiter Chancen an der Börse? Wallstreet Live mit Tim Schäfer

In diesem Interview sprechen wir mit Tim Schäfer direkt aus New York über die sogenannten „Magnificent 7“ – also die grossen Tech-Giganten wie Microsoft, Apple, Amazon, Tesla oder NVIDIA. Nach dem riesigen KI-Hype der letzten Jahre stellt sich die Frage: Sind die Aktien noch attraktiv oder bereits zu teuer?

https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Magnificent 7 im Check – Hype vorbei oder weiter Chancen an der Börse? Wallstreet Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 14’043.46 19.89 SYGBMU
Short 14’329.28 13.98 SWOBGU
Short 14’865.64 9.00 SJUBNU
SMI-Kurs: 13’507.82 28.05.2026 17:06:34
Long 12’920.59 19.33 SU3B7U
Long 12’644.83 13.91 SI6BUU
Long 12’074.28 8.82 SGSB6U
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

Aktien in diesem Artikel

Ottobock 52.60 -3.49% Ottobock